KR102701634B1 - 인지 장애를 치료 또는 예방하기 위한 인간화된 항체, 이것을 생산하는 공정, 및 이것을 사용하여 인지 장애를 치료 또는 예방하기 위한 제제 - Google Patents

인지 장애를 치료 또는 예방하기 위한 인간화된 항체, 이것을 생산하는 공정, 및 이것을 사용하여 인지 장애를 치료 또는 예방하기 위한 제제 Download PDF

Info

Publication number
KR102701634B1
KR102701634B1 KR1020197024146A KR20197024146A KR102701634B1 KR 102701634 B1 KR102701634 B1 KR 102701634B1 KR 1020197024146 A KR1020197024146 A KR 1020197024146A KR 20197024146 A KR20197024146 A KR 20197024146A KR 102701634 B1 KR102701634 B1 KR 102701634B1
Authority
KR
South Korea
Prior art keywords
seq
amino acid
acid sequence
antibody
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197024146A
Other languages
English (en)
Korean (ko)
Other versions
KR20190122674A (ko
Inventor
히로시 에구치
다카시 무라카미
나오코 나미키
아키라 다노쿠라
잔느 이. 베이커
소피 파멘티어 바퇴르
안젤라 마리 자블론스키
대니얼 스티븐 말라쇼크
칼 미에츠코브스키
고팔란 라구나단 (라구)
Original Assignee
데이진 화-마 가부시키가이샤
머크 샤프 앤드 돔 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이진 화-마 가부시키가이샤, 머크 샤프 앤드 돔 엘엘씨 filed Critical 데이진 화-마 가부시키가이샤
Publication of KR20190122674A publication Critical patent/KR20190122674A/ko
Application granted granted Critical
Publication of KR102701634B1 publication Critical patent/KR102701634B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197024146A 2017-02-27 2018-02-27 인지 장애를 치료 또는 예방하기 위한 인간화된 항체, 이것을 생산하는 공정, 및 이것을 사용하여 인지 장애를 치료 또는 예방하기 위한 제제 Active KR102701634B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017035594A JP2018139530A (ja) 2017-02-27 2017-02-27 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
JPJP-P-2017-035594 2017-02-27
PCT/IB2018/000249 WO2018154390A1 (en) 2017-02-27 2018-02-27 Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same

Publications (2)

Publication Number Publication Date
KR20190122674A KR20190122674A (ko) 2019-10-30
KR102701634B1 true KR102701634B1 (ko) 2024-08-30

Family

ID=62025891

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024146A Active KR102701634B1 (ko) 2017-02-27 2018-02-27 인지 장애를 치료 또는 예방하기 위한 인간화된 항체, 이것을 생산하는 공정, 및 이것을 사용하여 인지 장애를 치료 또는 예방하기 위한 제제

Country Status (27)

Country Link
US (3) US10556950B2 (https=)
EP (1) EP3585810B1 (https=)
JP (4) JP2018139530A (https=)
KR (1) KR102701634B1 (https=)
CN (2) CN111320695B (https=)
AR (2) AR110875A1 (https=)
AU (1) AU2018224390C1 (https=)
BR (1) BR112019016490A2 (https=)
CA (1) CA3052538A1 (https=)
CL (3) CL2019002296A1 (https=)
CO (1) CO2019008786A2 (https=)
CR (1) CR20190363A (https=)
DO (1) DOP2019000215A (https=)
EA (1) EA201991726A1 (https=)
ES (1) ES3063126T3 (https=)
GE (2) GEP20227392B (https=)
IL (1) IL267945B2 (https=)
JO (1) JOP20180014A1 (https=)
MA (1) MA47608A (https=)
MX (2) MX2019009945A (https=)
MY (1) MY193821A (https=)
NI (1) NI201900086A (https=)
PE (2) PE20191614A1 (https=)
PH (1) PH12019501929A1 (https=)
SG (2) SG10201913419TA (https=)
TW (2) TWI848904B (https=)
WO (2) WO2018154392A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
US20210355199A1 (en) 2018-06-28 2021-11-18 University Of Virginia Patent Foundation Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling
US12365724B2 (en) * 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
US20220381790A1 (en) 2019-02-11 2022-12-01 University Of Virginia Patent Foundation Selection and blockade of fertilization competent male and female gametes
EP3934677A4 (en) 2019-03-13 2022-11-16 University of Virginia Patent Foundation COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION
JP7181438B2 (ja) * 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
CN115605594A (zh) * 2020-06-02 2023-01-13 帝人制药株式会社（Jp） 抗igf-1受体人源化抗体
CA3183835A1 (en) * 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN115322255B (zh) * 2022-04-25 2025-03-07 上海药明生物医药有限公司 一种优化的Fc变体及其应用
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025207501A1 (en) * 2024-03-26 2025-10-02 Merck Sharp & Dohme Llc Crystals of anti-human tau monoclonal antibody
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087861A1 (en) 2010-10-11 2012-04-12 Roger Nitsch Human Anti-Tau Antibodies
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
WO2015200806A2 (en) 2014-06-27 2015-12-30 C2N Diagnostics Llc Humanized anti-tau antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
JP4754352B2 (ja) 2003-08-29 2011-08-24 株式会社リバース・プロテオミクス研究所 タンパク質の固定化方法
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
MY164376A (en) 2010-10-07 2017-12-15 Univ Leuven Kath Phosphospecific antibodies recognizing tau
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
BR112015030356A2 (pt) 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
WO2016112078A2 (en) 2015-01-08 2016-07-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120087861A1 (en) 2010-10-11 2012-04-12 Roger Nitsch Human Anti-Tau Antibodies
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
WO2015200806A2 (en) 2014-06-27 2015-12-30 C2N Diagnostics Llc Humanized anti-tau antibodies

Also Published As

Publication number Publication date
AR117952A2 (es) 2021-09-08
EA201991726A1 (ru) 2020-01-30
TW202506718A (zh) 2025-02-16
CL2021002389A1 (es) 2022-04-22
AU2018224390A1 (en) 2019-07-11
MY193821A (en) 2022-10-27
JP2018139530A (ja) 2018-09-13
MX2023013246A (es) 2023-11-21
CL2019002296A1 (es) 2019-11-29
JP2020508666A (ja) 2020-03-26
CN111320695B (zh) 2021-09-03
CL2024000339A1 (es) 2024-08-16
CN110382528A (zh) 2019-10-25
AR110875A1 (es) 2019-05-08
US10894829B2 (en) 2021-01-19
CO2019008786A2 (es) 2019-08-20
JOP20180014A1 (ar) 2019-01-30
CR20190363A (es) 2019-11-05
JP2023002670A (ja) 2023-01-10
GEP20227392B (en) 2022-06-27
AU2018224390C1 (en) 2025-04-17
BR112019016490A2 (pt) 2020-04-07
GEAP202215170A (en) 2022-02-10
ES3063126T3 (en) 2026-04-15
TWI848904B (zh) 2024-07-21
SG10201913419TA (en) 2020-03-30
JP7165996B2 (ja) 2022-11-07
CA3052538A1 (en) 2018-08-30
WO2018154392A1 (en) 2018-08-30
IL267945B1 (en) 2025-06-01
AU2018224390B2 (en) 2024-10-31
NI201900086A (es) 2019-10-08
US20210380677A1 (en) 2021-12-09
US20180346564A1 (en) 2018-12-06
US10556950B2 (en) 2020-02-11
CN111320695A (zh) 2020-06-23
DOP2019000215A (es) 2019-09-30
US20200223916A1 (en) 2020-07-16
EP3585810B1 (en) 2025-11-26
JP2024170459A (ja) 2024-12-10
US11739143B2 (en) 2023-08-29
PH12019501929A1 (en) 2020-06-29
EP3585810A1 (en) 2020-01-01
KR20190122674A (ko) 2019-10-30
IL267945A (en) 2019-09-26
WO2018154390A1 (en) 2018-08-30
IL267945B2 (en) 2025-10-01
TW201843179A (zh) 2018-12-16
PE20191614A1 (es) 2019-11-05
SG11201907548PA (en) 2019-09-27
MA47608A (fr) 2020-01-01
MX2019009945A (es) 2019-11-05
PE20241514A1 (es) 2024-07-19

Similar Documents

Publication Publication Date Title
KR102701634B1 (ko) 인지 장애를 치료 또는 예방하기 위한 인간화된 항체, 이것을 생산하는 공정, 및 이것을 사용하여 인지 장애를 치료 또는 예방하기 위한 제제
US12312411B2 (en) Anti-CD38 binding domains
CN116723856A (zh) 靶向丝氨酸413处磷酸化的tau的高亲和力抗体
CN111183153A (zh) Cd3/cd33双特异性结合分子
TW201904996A (zh) Ｐｃｓｋ９抗體、其抗原結合片段及其醫藥用途
JP2023508439A (ja) 治療ｆｃ組成物の化学誘導会合および解離ならびにｔ細胞エンゲージャーとヒト血清アルブミンとの化学誘導二量体形成
CN121057752A (zh) 铰链经修饰的双特异性抗体
HK40013632A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
EA048178B1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
EA040482B1 (ru) Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением
CN119546636A (zh) FcRn-结合多肽及其用途
JP2026507191A (ja) Ｍｕｃ１抗体及び使用方法
BR122024019353A2 (pt) Anticorpos anti-pser413 tau, anticorpos humanizados, molécula de ácido nucleico, vetor ou plasmídeo, composições compreendendo os mesmos, células hospedeiras, métodos para preparação dos referidos anticorpos, uso dos mesmos e agente para tratar ou prevenir demência

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190819

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210222

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220901

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230926

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240828

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240828

End annual number: 3

Start annual number: 1

PG1601 Publication of registration